MNG833
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.679
- INTERFERON_GAMMA_RESPONSE+0.484
- PROTEIN_SECRETION+0.338
- DNA_REPAIR+0.272
- OXIDATIVE_PHOSPHORYLATION+0.269
- MYC_TARGETS_V1+0.241
- UNFOLDED_PROTEIN_RESPONSE+0.182
- ALLOGRAFT_REJECTION+0.179
- PI3K_AKT_MTOR_SIGNALING+0.179
- E2F_TARGETS+0.092
Top 10 suppressed
- ANGIOGENESIS-0.486
- HYPOXIA-0.414
- TNFA_SIGNALING_VIA_NFKB-0.374
- ESTROGEN_RESPONSE_LATE-0.311
- MYOGENESIS-0.307
- WNT_BETA_CATENIN_SIGNALING-0.277
- ESTROGEN_RESPONSE_EARLY-0.276
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.275
- P53_PATHWAY-0.264
- COAGULATION-0.236
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R137 | — | — | 0.797 |
| 2 | 88302 | EPN | Supratentorial EPN | 0.796 |
| 3 | MNG85 | — | — | 0.793 |
| 4 | SRR9879266 | — | cohortMD2 | 0.789 |
| 5 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.777 |
| 6 | MNG547 | — | — | 0.775 |
| 7 | SRR25617870 | — | C | 0.775 |
| 8 | 223494f1-6c0b-446e-998d-53b3b4d0da1a | — | — | 0.773 |
| 9 | 004589d9-7eb6-46cb-b822-20cd1939aa7e | — | — | 0.771 |
| 10 | SRR12202424 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.679 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.484 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.338 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.272 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.269 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.241 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.182 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.179 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.179 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.092 | Inavolisib | — uncovered |
| PEROXISOME | 0.076 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.074 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.073 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.063 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.062 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.059 | Inavolisib | — uncovered |
| COMPLEMENT | 0.033 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |